Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Metrics to compare | PHVS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHVSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.8x | −0.3x | −0.5x | |
PEG Ratio | 0.69 | 0.00 | 0.00 | |
Price/Book | 4.6x | 0.2x | 2.6x | |
Price / LTM Sales | - | 3.9x | 3.3x | |
Upside (Analyst Target) | 57.3% | 261.4% | 46.2% | |
Fair Value Upside | Unlock | 40.5% | 6.6% | Unlock |